Catalyst Brief

← Calendar

Readoutin 76d

Pfizer — PF-06821497

Phase 3 primary completion: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1)..

Date
Feb 2027
Type
Readout
Indication
Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Pfizer

  1. Jan2027